Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35

Molecular Brain Research

Volumn 106, Issue 1-2, 2002, Pages 50-56

  Kerokoski, Petri ^a   Suuronen, Tiina ^a   Salminen, Antero ^a,b   Soininen, Hilkka ^a,b   Pirttilaä, Tuula ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Calpain; Glutamate; Okadaic acid; Proteasome

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALPAIN; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; LACTACYSTIN; OKADAIC ACID; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P35; ROSCOVITINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CELL CULTURE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANIMALS, NEWBORN; BRAIN CHEMISTRY; CALPAIN; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; CYSTEINE ENDOPEPTIDASES; EMBRYO; ENZYME INHIBITORS; HIPPOCAMPUS; MULTIENZYME COMPLEXES; NERVE TISSUE PROTEINS; NEURONS; OKADAIC ACID; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PURINES; RATS; RATS, WISTAR;

EID: 0037109186     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(02)00409-6     Document Type: Article

References (22)

1. Brion J.P., Couck A.M. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am. J. Pathol. 147:1995;1465-1476.
2. Chae T., Kwon Y.T., Bronson R., Dikkes P., Li E., Tsai L.H. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 18:1997;29-42.
3. Fletcher A.I., Shuang R., Giovannucci D.R., Zhang L., Bittner M.A., Stuenkel E.L. Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18. J. Biol. Chem. 274:1999;4027-4035.
4. Green S.L., Kulp K.S., Vulliet R. Cyclin-dependent protein kinase 5 activity increases in rat brain following ischemia. Neurochem. Int. 31:1997;617-623.
5. Hayashi T., Warita H., Abe K., Itoyama Y. Expression of cyclin-dependent kinase 5 and its activator p35 in rat brain after middle cerebral artery occlusion. Neurosci. Lett. 265:1999;37-40.
6. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439.
7. Kerokoski P., Suuronen T., Salminen A., Soininen H., Pirttilä T. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis. Biochem. Biophys. Res. Commun. 280:2001;998-1002.
8. Kusakawa G.-I., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S.-I. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275:2000;17166-17172.
9. Lee M.-S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.-H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
10. Lew J., Huang Q.-Q., Qi Z., Winkfein R.J., Aebersold R., Hunt T., Wang J.H. A brain-specific activator of cyclin-dependent kinase 5. Nature. 371:1994;423-426.
11. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
12. nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol. 94:1997;153-157.
13. Nath R., Davis M., Probert A.W., Kupina N.C., Ren X., Schielke G.P., Wang K.K.W. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 274:2000;16-21.
14. Nikolic M., Dudek H., Kwon Y.T., Ramos Y.F.M., Tsai L.-H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10:1996;816-825.
15. Patrick G.N., Zhou P., Kwon Y.T., Howley P.M., Tsai L.-H. p35, the neuronal specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273:1998;24057-24064.
16. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.-H. Conversion of p35 to p25 deregulates cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
17. Pei J.-J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797:1998;267-277.
18. Ratner N., Bloom G.S., Brady S.T. A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein. J. Neurosci. 18:1998;7717-7726.
19. Saito T., Ishiguro K., Onuki R., Nagai Y., Kishimoto T., Hisanaga S.-I. Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons. Biochem. Biophys. Res. Commun. 252:1998;775-778.
20. Taniguchi S., Fujita Y., Hayashi S., Kakita A., Takahashi H., Murayama S., Saido T.C., Hisanaga S., Iwatsubo T., Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 489:2001;46-50.
21. Tsai L.-H., Delalle I., Caviness V.S. Jr., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 371:1994;419-423.
22. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92:1996;232-241.